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Abstract
Purpose A substantial proportion of amyloid-β (Aβ)+ patients with clinically diagnosed Alzheimer’s disease (AD) dementia and
mild cognitive impairment (MCI) are tau PET–negative, while some clinically diagnosed non-AD neurodegenerative disorder
(non-AD) patients or cognitively unimpaired (CU) subjects are tau PET–positive. We investigated which demographic, clinical,
genetic, and imaging variables contributed to tau PET status.
Methods We included 2338 participants (430 Aβ+ AD dementia, 381 Aβ+ MCI, 370 non-AD, and 1157 CU) who underwent
[18F]flortaucipir (n = 1944) or [18F]RO948 (n = 719) PET. Tau PET positivity was determined in the entorhinal cortex, temporal
meta-ROI, and Braak V-VI regions using previously established cutoffs. We performed bivariate binary logistic regression
models with tau PET status (positive/negative) as dependent variable and age, sex, APOEε4, Aβ status (only in CU and non-
AD analyses), MMSE, global white matter hyperintensities (WMH), and AD-signature cortical thickness as predictors.
Additionally, we performed multivariable binary logistic regression models to account for all other predictors in the same model.
Results Tau PET positivity in the temporal meta-ROI was 88.6% for AD dementia, 46.5% for MCI, 9.5% for non-AD, and 6.1%
for CU. Among Aβ+ participants with AD dementia and MCI, lower age, MMSE score, and AD-signature cortical thickness
showed the strongest associations with tau PET positivity. In non-AD and CU participants, presence of Aβ was the strongest
predictor of a positive tau PET scan.
Data used in preparation of this article were obtained from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(adni.loni.usc.edu). As such, the investigators within the ADNI contribut-
ed to the design and implementation of ADNI and/or provided data but
did not participate in analysis or writing of this report. A complete listing
of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-
content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Data used in preparation of this article were obtained from the Pre-
symptomatic Evaluation of Novel or Experimental Treatments for
Alzheimer’s Disease (PREVENT-AD) program (https://douglas.
research.mcgill.ca/stop-ad-centre). A complete listing of PREVENT-AD
Research Group can be found in the PREVENT-AD database: https://
preventad.loris.ca/acknowledgements/acknowledgements.php?date=
[2020-09-08]†.
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Conclusion We identified several demographic, clinical, and neurobiological factors that are important to explain the variance in
tau PET retention observed across the AD pathological continuum, non-AD neurodegenerative disorders, and cognitively
unimpaired persons.
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Introduction
Tau accumulation is a key neuropathological feature of
Alzheimer’s disease (AD) and is closely linked to synaptic loss,
neurodegeneration, and cognitive deficits [1]. The advent of
positron emission tomography (PET) ligands with high affinity
for the tau aggregates formed in AD now enables the visuali-
zation and quantification of tau pathology in vivo [2]. Recently,
one of these tau PET tracers ([18F]flortaucipir) was approved by
the US Food and Drug Administration to support the diagnostic
process in patients with suspected AD dementia [3]. This is an
important step towards the clinical application of tau PET.
However, several hurdles need to be overcome in order to
accelerate the transition of tau PET from an investigational
technique to a diagnostic biomarker. One of these challenges
is the observation of negative tau PET scans in individuals
suspected of having symptomatic AD [4–7] or, conversely,
positive tau PET scans in individuals suspected for a non-
AD neurodegenerative disorder like frontotemporal lobar de-
generation (behavioral or language phenotype) or
Parkinsonian disorders [5, 6, 8, 9]. This can potentially ham-
per the interpretation of the tau PET result or lead to subopti-
mal patient selection for a clinical tau PET scan. A better
understanding of factors that contribute to tau PET status
could alleviate this concern.
Based on previous literature [4, 7, 8, 10–23] and data avail-
ability, we evaluated in this large multicenter study the impact
of demographic (age and sex), clinical (Mini-Mental State
Examination [MMSE]), genetic (apolipoprotein [APOE] geno-
type), and imaging (cortical thickness, white matter
hyperintensities [WMH], and amyloid-β [Aβ] status) variables
on tau PET status across persons with AD dementia, mild
cognitive impairment (MCI), and non-AD neurodegenerative
disorders, and cognitively unimpaired (CU) individuals.
Material and methods
Participants
We included 2338 participants from the Memory Disorder
Clinic of Gangnam Severance Hospital (Seoul, South Korea,
n = 310) and the Swedish BioFINDER 1 (n = 228) and 2 (n =
719) studies at Lund University (Lund, Sweden), the
University of California San Francisco (UCSF) AD
Research Center (San Francisco, USA, n = 201), the
PREVENT-AD study (n = 134), the Alzheimer’s disease neu-
roimaging ini t ia t ive (ADNI, n = 655) , and Avid
Radiopharmaceuticals studies (A04 [n = 36], A05 [n = 219],
A08 [n = 76], and the placebo arm of the Eli Lilly
solanezumab Expedition-3 study [n = 85]). Of these partici-
pants, 1695 (72.5%) underwent [18F]flortaucipir PET and
643 (27.5%) [18F]RO948 PET. According to the NIA-AA
diagnostic criteria [24, 25] and a research framework [26],
we only included Aβ+ AD dementia (n = 430) and MCI
(n = 381) patients (determined using PET and/or CSF, see
previous work for details [5, 6]). A total of 370 participants
were diagnosed with a non-AD neurodegenerative disorder
according to formal diagnostic criteria [5, 6], including
Parkinson’s disease (n = 123), progressive supranuclear palsy
(n = 58), dementia with Lewy bodies (n = 51), behavioral var-
iant frontotemporal dementia (n = 50), corticobasal syndrome
(n = 27), the semantic (n = 19) and non-fluent (n = 17) variants
of primary progressive aphasia, multiple system atrophy (n =
12), and dementia not otherwise specified (n = 14). CU indi-
viduals (n = 1157) performed within normal limits on neuro-
psychological testing and had no significant neurological or
psychiatric illnesses. In addition to tau PET, all participants
underwent a medical history and neurological examination,
MRI, and neuropsychological testing. Written informed con-
sent was obtained from all participants, and local institutional
review boards for human research approved the study. The
study was performed in accordance with the ethical standards
as laid down in the 1964 Declaration of Helsinki and its later
amendments or comparable ethical standards.
Acquisition of PET and MRI data
PET images were acquired using a Biograph mCT PET/CT
scanner (SiemensMedical Solutions) in Seoul [11]; Discovery
and Discovery MI PET scanners (GE medical systems) in
BioFINDER 1 and 2, respectively [5, 6]; a Biograph 6
Truepoint PET/CT scanner (Siemens Medical Solutions) for
UCSF patients [18], a Siemens High-Resolution Research
Tomograph (HRRT) scanner in PREVENT-AD [15], and
across multiple scanners in the multi-center ADNI [27] and
Avid Radiopharmaceuticals [7] cohorts. All PET data were
locally reconstructed into 4 × 5-min frames for the 80–100-
min ([18F]flortaucipir) and 70–90-min ([18F]RO948) intervals
post-injection. MR images were acquired on a 3.0T Discovery
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MR750 scanner (GE medical systems) in Seoul [11], 3.0T
Tim Trio or Skyra scanner (Siemens Medical Solutions) in
BioFINDER [5, 6], a 3.0T Tim Trio or Prisma scanner
(Siemens Medical Solutions) at UCSF [18], a 3.0 Tim Trio
scanner (Siemens Medical Solutions) in PREVENT-AD [15],
and across multiple scanners in the multi-center ADNI [27]
and Avid Radiopharmaceuticals [7] cohorts.
T1-weighted MRI processing
MRI data were centrally processed (at LundUniversity), using
previously reported procedures [5, 6]. Briefly, cortical recon-
struction and volumetric segmentation were performed with
the FreeSurfer (v6.0) image analysis pipelines (http://surfer.
nmr.mgh.harvard.edu/). The MP-RAGE images underwent
correction for intensity homogeneity [28], removal of non-
brain tissue [29], and segmentation into gray matter (GM)
and white matter (WM) with intensity gradient and connectiv-
ity among voxels [30]. Cortical thickness was measured as the
distance from the GM/WM boundary to the corresponding
pial surface [31]. Reconstructed data sets were visually
inspected for accuracy, and segmentation errors were
corrected. We computed “AD-signature” cortical thickness
[32] comprising bilateral entorhinal, inferior and middle tem-
poral, and fusiform cortex regions of interest (ROI).
[18F]flortaucipir PET processing
PET images were first re-sampled to obtain the same image size
(128 × 128 × 63 matrix) and voxel dimensions (2.0 × 2.0 ×
2.0 mm) across centers. Next, PET images were centrally proc-
essed (at Lund University) using previously reported procedures
[5, 6]. [18F]Flortaucipir images were motion-corrected using
AFNI’s 3dvolreg, time-averaged and rigidly co-registered to
the skull-stripped MRI scan. Voxelwise standardized uptake
value ratio (SUVR) images were created using inferior cerebel-
lar gray matter as the reference region [33]. FreeSurfer (v6.0)
parcellation of the T1-weighted MRI scan was applied to the
PET data transformed to subjects’ native T1 space to extract
mean regional SUVR values. In line with our previous work
[5, 6], we calculated the mean [18F]flortaucipir and
[18F]RO948 SUVR in the entorhinal cortex (early tau region),
a temporal meta-ROI [32] comprised of a weighted average of
entorhinal, amygdala, parahippocampal, fusiform, and inferior
and middle temporal ROIs (intermediate tau region), and Braak
stage V/VI encompassing widespread neocortical ROIs (late tau
region). As tau PET positivity can be established using a variety
of methods, we aimed to be consistent with our earlier work and
use previously published and validated procedures for both
tracers [5, 6]. Hence, we determined tau PET positivity in each
of the aforementioned regions using the mean of elderly (69.1 ±
9.5 years) CU subjects + (2 * SD) for [18F]flortaucipir [6] and
the mean of young (30.5 ± 6.6 years) Aβ-negative CU subjects
+ (2.5 * SD) [18F]RO948 [5]. This resulted in cutoffs of 1.39
(entorhinal cortex), 1.34 (temporal meta-ROI), and 1.28 (Braak
V-VI) SUVR for [18F]flortaucipir, and 1.48 (entorhinal cortex),
1.36 (temporal meta-ROI), and 1.35 (Braak V-VI) SUVR for
[18F]RO948.
FLAIR MRI processing
T2-weighted fluid attenuated inversion recovery (FLAIR) im-
ages were available for 1660/2338 (71.0%) participants. We
estimated total WMH volumes following a segmentation
method described elsewhere [34]. Briefly, this method builds
a Bayesian probabilistic data model based on a Gaussian mix-
ture model with an evolving number of components. Due to
distribution skewness, data were log-transformed prior to sta-
tistical analysis.
Statistical analyses
To identify factors associated with tau PET positivity, we
performed bivariate binary logistic regression models with
tau PET status (positive/negative) in the three preselected re-
gions (i.e., entorhinal cortex, temporal meta-ROI, and Braak
V-VI) as dependent variable, and age, sex, APOE ε4 status,
Aβ status (only in analyses including participants with a non-
AD neurodegenerative disorder and CU individuals), MMSE,
total WMH volumes (adjusted for intracranial volume), and
AD-signature cortical thickness as predictors. Values for AD-
signature cortical thickness and total WMH were divided by
10 and 1000 respectively, to obtain odds ratios in a compara-
ble range to the other variables. Additionally, we performed
multivariable binary logistic regression models to account for
all other predictors in the same model. We excluded total
WMH from the multivariable analysis due to a significant
proportion (29%) of missing data. Finally, we conducted a
post hoc analyses to estimate at which MMSE score the tau
PET scan would be robustly positive in Aβ-positive partici-
pants with AD dementia and MCI. Using a non-parametric
regression method (i.e., locally estimated scatterplot smooth-
ing [35]), we computed theMMSE score at which the tau PET
thresholds diverged from the 95% confidence interval of the
slope reflecting tau PET SUVR vs MMSE scores.
Significance level was set at 2-sided P < 0.05. We used R
v3.5.2 for the statistical analyses.
Results
Participants
The participant characteristics across diagnostic groups are
presented in Table 1. Overall, the study participants were
69.4 ± 10.2 years old and 53.2% were males. By definition,
2247Eur J Nucl Med Mol Imaging (2021) 48:2245–2258
all AD dementia and MCI patients were Aβ positive, and
65.5% (AD dementia) and 61.8% (MCI) carried at least one
APOE ε4 allele. In the non-AD neurodegenerative disorder
and CU group, 29.0% and 34.3% were Aβ positive and
32.5% and 35.7% APOE ε4 positive, respectively. Figure 1
shows the distribution of tau PET SUVR values and the pos-
itivity rates across the three ROIs, stratified by tau PET tracer.
In the temporal meta-ROI, tau PET positivity was observed in
1.5% of Aβ-negative CU, 2.2% of Aβ-negative non-AD,
14.7% of Aβ-positive CU, 27.7% of Aβ-positive non-AD,
46.5% of Aβ-positive MCI, and 88.6% of Aβ-positive AD
dementia.
Tau PET positivity in amyloid-β+ AD dementia
Bivariate and multivariable binary logistic regression models
in patients with Aβ+ AD dementia are presented in Table 2.
The multivariable analysis indicated that younger age and
lower MMSE scores were associated with higher rates of tau
positivity across all ROIs. In addition, lower AD-signature
cortical thickness was associated with higher rates of tau pos-
itivity in the temporal meta-ROI and the Braak V/VI ROI, and
the presence of an APOE ε4 allele was associated with a
higher rate of tau positivity in the temporal meta-ROI only.
There were no significant associations between sex and tau
PET positivity in both bivariate and multivariable models.
WMH volumes were excluded from themultivariable analysis
due to missing data, but bivariate models revealed no signif-
icant associations between globalWMHvolumes and tau PET
positivity.
Tau PET positivity in amyloid-β+ MCI
Bivariate and multivariable binary logistic regression models
in patients with Aβ+ MCI are presented in Table 3. The
multivariable analysis indicated that lower MMSE scores
and lower AD-signature cortical thickness were associated
with higher rates of tau positivity across all ROIs. In addition,
presence of an APOE ε4 allele was associated with higher
rates of tau positivity in the entorhinal cortex and temporal
meta-ROI, and lower age was associated with a higher rate
of tau positivity in the Braak V/VI ROI. There were no sig-
nificant associations between sex and tau PET positivity in the
multivariable models, but male sex was associated with a
higher rate of tau positivity in the entorhinal cortex in the
bivariate model. WMH volumes were excluded from the mul-
tivariable analysis due to missing data. The bivariate analysis
indicated a significant association between global WMH vol-
umes and tau PET positivity in the entorhinal cortex, but not in
the temporal meta-ROI or the Braak V/VI ROI.
Since a lower MMSE score was consistently associated
with higher rates of tau PET positivity across all ROI for both
Aβ+ MCI and AD dementia, we performed a post hoc anal-
ysis to estimate around which MMSE score the tau PET is
robustly positive (Fig. 2). This analysis indicated that the 95%
confidence interval did not overlap with the tau PET positivity
threshold at an MMSE of 27.6 ([18F]flortaucipir) or 26.0
( [ 1 8F ]RO948 ) f o r t h e en t o r h i n a l co r t e x , 29 . 1
([18F]flortaucipir) or 26.6 ([18F]RO948) for the temporal me-
ta-ROI, and 22.2 ([18F]flortaucipir) or 21.9 ([18F]RO948) for
the Braak V/VI ROI.
Tau PET positivity in non-AD neurodegenerative
disorders
Bivariate and multivariable binary logistic regression models
in patients with a clinically diagnosed non-AD neurodegener-
ative disorder are presented in Table 4. The bivariate analysis
indicated that most variables (except for sex) were associated
with higher rates of tau positivity, especially in the entorhinal
Table 1 Participant characteristics
Aβ+ AD dementia Aβ+ mild cognitive impairment Non-AD neurodegenerative
disorders
Cognitively unimpaired
N 430 381 370 1157
Age 71.5 (8.9) 71.6 (8.0) 69.4 (8.1) 67.9 (11.8)
Sex (% male) 55.6 46.5 53.5 55.3
APOE ε4 (% positive) 65.5 61.8 32.5 35.7
Amyloid-β (% positive) 100 100 29.0 34.3
MMSE 20.8 (4.5) 27.0 (2.4) 24.2 (5.5) 29.0 (1.3)
[18F]flortaucipir/[18F]RO948 (n) 313/117 275/106 247/123 860/297
AD-signature cortical thickness, mm 2.41 (0.19) 2.60 (0.20) 2.57 (0.23) 2.74 (0.14)
Global WMH volumes, log mm3 3.71 (0.48) 3.68 (0.48) 3.62 (0.44) 3.48 (0.45)
Data are presented as mean (standard deviation), unless otherwise stated
AD Alzheimer’s disease, APOE apolipoprotein E, MMSE Mini-Mental State Examination, WMH white matter hyperintensities
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cortex and temporal meta-ROI, with Aβ positivity consistent-
ly showing the strongest associations. In the multivariable
analysis, only Aβ positivity and lower MMSE scores
remained significantly associated with higher rates of tau pos-
itivity in the entorhinal cortex and temporal meta-ROI. There
were only 13 tau PET–positive cases in the Braak V-VI ROI
(12 of them being Aβ positive), warranting cautious interpre-
tation of these results.
Tau PET positivity in cognitively unimpaired
individuals
Bivariate and multivariable binary logistic regression models
in CU participants are presented in Table 5. The bivariate
analysis indicated that most variables (except for sex) were
associated with higher rates of tau positivity, especially in
the entorhinal cortex and temporal meta-ROI, with Aβ posi-
tivity consistently showing the strongest associations. In the
multivariable analysis with tau PET positivity in the entorhi-
nal cortex as the dependent variable, older age, presence of an
APOE ε4 allele, Aβ positivity, lower MMSE, and lower AD-
signature cortical thickness were associated with higher rates
of tau positivity. For the temporal meta-ROI, significant
associations were found for older age, male sex, and Aβ pos-
itivity. For the Braak V/VI ROI, significant associations were
found for male sex only.
Discussion
In this large multicenter study, we investigated how demo-
graphic (age and sex), clinical (MMSE), genetic (APOE ge-
notype), and imaging/CSF (AD-signature cortical thickness,
global WMH volumes, and Aβ status) variables were associ-
ated with tau PET status defined using previously established
quantitative thresholds for [18F]flortaucipir and [18F]RO948.
In Aβ-positive AD dementia and MCI, younger age, lower
MMSE scores, and lower AD-signature cortical thickness
showed the strongest associations with tau PET positivity. In
non-AD neurodegenerative disorders and CU participants, the
presence of Aβ was the strongest predictor of a positive tau
PET scan. We thus identified several demographic, clinical,
and neurobiological factors that are important to explain the
variance in tau PET retention observed across the AD patho-
logical continuum, non-AD neurodegenerative disorders, and
CU persons.
Fig. 1 The y-axis represents the SUVR values for [18F]flortaucipir (FTP,
panel a–c) and [18F]RO948 (panel d–f) for the entorhinal cortex (a and
d), temporal meta-ROI (b and e), and Braak V/VI ROI for Aβ+
Alzheimer ’s disease (AD) dementia , Aβ+ MCI, non-AD
neurodegenerative disorders, and cognitively unimpaired (CU)
participants. The percentages on top of each panel represent the
proportion of tau PET–positive cases based on previously established
cutoffs
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Among Aβ-positive participants clinically diagnosed with
AD dementia, the main predictors of a negative tau PET scan
were older age and a higher MMSE score. At older age, a lower
tau burden might be sufficient to produce a dementia syndrome
due to the co-occurrence of other age-related pathologies (e.g.,
TDP-43, α-synuclein, or vascular pathology, [36, 37]) that con-
tribute to cognitive decline (i.e., the “double-hit hypothesis” [38])
or to reduced efficiency of functional repair mechanisms associ-
ated with chronological aging that may magnify the cognitive
consequences of tau pathology [16, 39]. Alternatively, in a pro-
portion of participants, their Aβ positivity may be comorbid to a
primary non-AD neurodegenerative disorder [40, 41], which
would explain the negative tau PET scan because
[18F]flortaucipir and [18F]RO948 seem to primarily bind to
“AD-like” tau pathology and less to the tau aggregates formed
in other tauopathies [42, 43]. A third explanation is the possibility
of a selection bias, as older participants with multiple pathologies
and other vulnerabilities who additionally have a high tau burden
would become too cognitively impaired to participate in clinical
research. The greater rates of tau PET–negative statuswith higher
MMSE scores may be explained by the restricted sensitivity of
both tau PET tracers [5, 6] that requires a significant pathological
tau burden in order to cross the quantitative threshold [44], or by
an inherent limitation of PET that requires a certain density of the
target (Bmax) to allow unambiguous detection. This finding is in
line with the drop in tau PET positivity rates in for example the
temporal meta-ROI from AD dementia (88% for both tracers) to
MCI (51% for [18F]flortaucipir and 36% for [18F]RO948). More
modest associations with tau PET positivity were found for
APOE ε4 status (temporal meta-ROI only) and lower AD-
signature cortical thickness (temporal meta-ROI and Braak V-
VI regions), and sex and global WMH volumes did not impact
tau PET status in Aβ-positive AD dementia.
In Aβ-positive MCI, the main predictors for tau PET pos-
itivity were lower MMSE scores and decreased AD-signature
cortical thickness. Both could be considered markers of dis-
ease progression, and in line with the findings in AD dementia
and previous literature, there is a tight link between the
amount of tau pathology and the level of neurodegeneration
and cognitive impairment [11, 19, 22, 45–48]. To a greater
degree than in AD dementia, APOE ε4 carriership was asso-
ciated with a positive tau PET scan in the entorhinal cortex
and temporal meta-ROI (but not in the Braak V/VI ROI),
which is in accordance with earlier reports of a temporal lobe
predilection of APOE ε4 [21, 49]. Furthermore, age played a
less prominent role at the MCI stage of AD, as there was only
a significant association with (younger) age and tau PET pos-
itivity in the Braak V/VI ROI. Sex and global WMH volumes
did not impact tau PET status in Aβ-positive MCI.
In participants with a non-AD neurodegenerative disorder,
positive Aβ status and lower MMSE scores were the only
significant predictors of tau PET positivity in the multivariable
models. The finding of positive Aβ status can be explained
twofold. First, it could be due to a clinical misdiagnosis with
AD as the primary pathological substrate for their dementia
syndrome [41, 50]. This would fit the observation of (lower)
MMSE as second predictor of tau PET positivity, as in more
advanced disease stages, it may become more difficult to dis-
entangle the symptomatic and radiological features across
neurodegenerative disorder and thus increase their clinical
and neuroanatomical overlap. Second, Aβ and tau pathology
could be present as secondary pathology, whereas the clinical
syndrome is driven by non-AD pathologies, as in aging pop-
ulations where multiple proteinopathies can emerge in tandem
[37]. It should be noted that in bivariate models, nearly all
variables (except for sex) were associated with tau PET pos-
itivity, with the directionality of these associations always in
line with AD risk factors (i.e., older age, APOE ε4 positivity,
lower MMSE, reduced AD-signature cortical thickness, and
elevated global white matter hyperintensity volumes), but
these associations did not survive in multivariable models
accounting for Aβ status. Finally, results for Braak V/VI re-
gions should be interpreted with caution, as only 13 partici-
pants were tau PET positive in this group.
Fig. 2 The graphs show non-linear associations between tau PET uptake
and MMSE scores for both [18F]flortaucipir and [18F]RO948. The
horizontal lines (dotted for [18F]flortaucipir and dashed for [18F]RO948)
indicate previously established cutoffs for tau PET positivity, while the
vertical lines indicate the MMSE score at which the 95% confidence
interval of the slope no longer overlaps with the respective tau PET
cutoff for each tracer
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In CU individuals, positive Aβ status and older age were the
strongest predictors of tau PET positivity in the entorhinal cortex
and temporal meta-ROI. This is in line with an extensive litera-
ture on the interplay between Aβ and tau pathology in aging
populations, suggesting that amyloid-β facilitates the neocortical
spread of tau pathology [51]. In addition, there is evidence for a
(possibly Aβ-independent) effect of advancing age on tau accu-
mulation in the medial temporal lobe, which would explain why
older age was only associated with tau PET positivity in the
entorhinal cortex and temporal meta-ROI, but not in the Braak
V-VI ROI. The multivariable model for the Braak V-VI ROI
indicated male sex as the only significant predictor of tau PET
status, but this finding should be interpreted with caution because
this association did not reach significance in the bivariate model
and the number of tau PET–positive CU participants in this ROI
was limited. Similar to the results for non-AD neurodegenerative
disorders, the bivariate models indicated that more “AD-like”
characteristics of the predictors (e.g., APOE ε4 positivity, lower
MMSE scores, and reduced AD-signature cortical thickness)
were associated with tau PET positivity.
Themain strengths of this study include the large sample size,
the wide variety of clinical diagnoses, and the use of predefined
cutoffs for tau PET positivity. There are also several limitations.
First, inherent to the retrospective multicenter study design, har-
monization between cohorts is complicated. For the imaging
data, we attempted to minimize variability by analyzing all data
centrally using an identical pipeline, but we acknowledge that
differences in data acquisition and pre-processing remain. There
likely also exists heterogeneity in the administration of the
MMSE and in determining Aβ status using PET or CSF, the
former likely being more conservative. Second, due to lack of
statistical power to perform the analyses in individual non-AD
neurodegenerative disorders, we combined them into a single
diagnostic group. It is possible that the study outcomes would
be different when focusing on specific non-AD neurodegenera-
tive disorders. Third, the number of CU individuals (n = 26,
2.3%) and participants with non-AD neurodegenerative disor-
ders (n = 13, 3.5%) who were tau PET positive in the Braak
V/VI ROI was low. In addition to early (entorhinal cortex) and
intermediate (temporal meta-ROI) tau regions, we aimed to also
examine a more advanced tau region (i.e., Braak V/VI), but these
results should be interpreted with caution. Fourth, we used two
different tau PET tracers in this study and defined tau PET pos-
itivity using different albeit predefined methods. Based on a pre-
vious head-to-head comparison between [18F]flortaucipir and
[18F]RO948 that demonstrated comparable neocortical tracer re-
tention [52], we deemed it appropriate to combine them in the
analyses. Fifth, some of the non-AD tauopathies included in this
study (e.g., Progressive supranuclear palsy (PSP) or Corticobasal
degeneration (CBD)) are characterized by specific isoforms of
tau (i.e., 4R in case of PSP and CBD) that are not sufficiently
detectable using [18F]flortaucipir or [18F]RO948 PET [5, 6].
With “tau PET positivity” in this study, we refer to the detection
of “AD-like” tau aggregates, and we acknowledge that tau PET
negativity does not exclude the presence of certain tau aggregates
typically observed in other tauopathies.
The recent US Food and Drug Administration approval for
use of [18F]flortaucipir PET to support the diagnostic process in
patients with suspected AD dementia represents an important
step towards application of tau PET in the clinic. The current
study identified several demographic, clinical, and neurobiolog-
ical factors that help explain the variance of tau PET retention
observed across the AD pathological continuum, non-AD neu-
rodegenerative disorders, and CU persons. This information
might be incorporated into decision trees tailored to optimize
patient selection for a clinical tau PET scan and to facilitate the
interpretation of tau PET images. Future studies should focus on
further development of visual read metrics [44], whether and
how a quantitative threshold approachwould add to a visual read,
how threshold approaches for different tau PET tracers relate to
each other and whether a standardized quantification approach
would be feasible, and which cutoff in which ROI provides
optimal diagnostic performance. This would be especially impor-
tant to increase the sensitivity of tau PET tracers to detect tau
pathology in early disease stages, while maintaining its excellent
specificity.
Funding Open access funding provided by Vrije Universiteit
Amsterdam. Work at Lund University was supported by the Swedish
Research Council, the Knut and Alice Wallenberg foundation, the
Marianne and Marcus Wallenberg foundation, the Strategic Research
Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at
Lund University, the Swedish Alzheimer Foundation, the Swedish
Brain Foundation, The Medical Faculty at Lund University, Region
Skåne, The Bundy Academy, The Parkinson foundation of Sweden,
The Parkinson Research Foundation, the Skåne University Hospital
Foundation, and the Swedish federal government under the ALF
agreement.
CHS is supported by an Alzheimer’s Society Junior Fellowship (AS-
JF-17-011).
Work at UCSF was supported by the following grants: P30-
AG062422 (BLM, GDR), P01-AG019724 (BLM, GDR), R01-
AG038791 (GDR), R01-NS050915 (MLGT), K99 AG065501 (RLJ),
R01 AG045611 (GDR), Alzheimer’s Association AACSF-19-617663
(DSM), Rainwater Charitable Foundation (GDR).
Doses of 18F-flutemetamol injection were sponsored by GE
Healthcare in BioFINDER-1. The precursor of 18F-flutemetamol was
sponsored by GE Healthcare in BioFINDER-2. The precursor of 18F-
flortaucipir was provided by Avid radiopharmaceuticals. The precursor
of 18F-RO948 was provided by Roche.
Data collection and sharing for this project was funded by the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National
Institutes of Health Grant U01 AG024904) and DOD ADNI
(Department of Defense award number W81XWH-12-2-0012). ADNI
is funded by the National Institute on Aging and the National Institute
of Biomedical Imaging and Bioengineering, and through generous con-
tributions from the following: AbbVie, Alzheimer’s Association;
Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica,
Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate;
Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company;
EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company
Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen
Alzheimer Immunotherapy Research & Development, LLC.; Johnson
2255Eur J Nucl Med Mol Imaging (2021) 48:2245–2258
& Johnson Pharmaceutical Research & Development LLC.; Lumosity;
Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx
Research; Neurotrack Technologies; Novartis Pharmaceuticals
Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda
Pharmaceutical Company; and Transition Therapeutics. The Canadian
Institutes of Health Research is providing funds to support ADNI clinical
sites in Canada. Private sector contributions are facilitated by the
Foundation for the National Institutes of Health (www.fnih.org). The
grantee organization is the Northern California Institute for Research
and Education, and the study is coordinated by the Alzheimer’s
Therapeutic Research Institute at the University of Southern California.
ADNI data are disseminated by the Laboratory for Neuro Imaging at the
University of Southern California.
PREVENT-AD was launched in 2011 as a $13.5 million, 7-year public–
private partnership using funds provided byMcGill University and the Fonds
de Recherche du Québec – Santé (FRQ-S), an unrestricted research grant
from Pfizer Canada, the J.L. Levesque Foundation, the Lemaire
Foundation, the Douglas Hospital Research Centre and Foundation, the
Government of Canada, and the Canada Fund for Innovation. The PET scans
were supported by an Alzheimer’s Association Grant, an Alzheimer Society
of Canada grant, and two Canada Institutes of Health Research grants (PJT-
162091 and PJT-148963).
Data availability Anonymized data from BioFINDER will be shared by
request from a qualified academic investigator for the sole purpose of repli-
cating procedures and results presented in the article and as long as data
transfer is in agreement with EU legislation on the general data protection
regulation and decisions by the Ethical Review Board of Sweden and Region
Skåne, which should be regulated in a material transfer agreement.
ADNI data can be downloaded from: www.adni.loni.usc.edu.
Most of the PREVENT-AD data can be downloaded from https://
registeredpreventad.loris.ca.
Compliance with ethical standards
Written informed consent was obtained from all participants, and local
institutional review boards for human research approved the study. The
study was performed in accordance with the ethical standards as laid
down in the 1964 Declaration of Helsinki and its later amendments or
comparable ethical standards.
Conflict of interest OH has acquired research support (for the institu-
tion) from Roche, Pfizer, GE Healthcare, Biogen, Eli Lilly, and AVID
Radiopharmaceuticals. In the past 2 years, he has received consultancy/
speaker fees (paid to the institution) from Biogen and Roche.
GDR receives research support from NIH, Alz Assoc, American
College of Radiology, Avid Radiopharmaceuticals, GE Healthcare, Life
Molecular Imaging. In the past 2 years he has received consulting fees
from Axon Neurosciences, Eisai, GE Healthcare, Johnson & Johnson,
and Merck. He is an Associate Editor for JAMA Neurology.
ALB receives research support from NIH (R01AG038791,
U19AG063911), the Tau Research Consortium, the Association for
Frontotemporal Degeneration, and the Bluefield Project to Cure
Frontotemporal Dementia. He has served as a consultant for AGTC,
Alector, Arkuda, Arvinas, Bioage, Ionis, Lundbeck, Passage BIO,
Samumed, Ono, Sangamo, Stealth, Third Rock, Transposon, UCB, and
Wave, and received research support from Avid, Eisai, Biogen, and Roche.
MJP andMDD are employees of Avid Radiopharmaceuticals, a whol-
ly owned subsidiary of Eli Lilly and Company, and are minor stock-
holders in Eli Lilly.
EB and GK are employees of F. Hoffmann-La Roche Ltd.
The other authors report no conflict of interest.
Code availability Code will be provided upon reasonable request.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Selkoe DJ. The molecular pathology of Alzheimer's disease.
Neuron. 1991;6:487–98. https://doi.org/10.1016/0896-6273(91)
90052-2.
2. Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O,
Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative
tauopathies-still a challenge. Mol Psychiatry. 2019;24:1112–34.
https://doi.org/10.1038/s41380-018-0342-8.
3. US Food & Drug administration. https://www.fda.gov/news-events/
press-announcements/fda-approves-first-drug-image-tau-pathology-
patients-being-evaluated-alzheimers-disease. Accessed 28 May 2020.
4. Jack CR, Wiste HJ, Botha H, Weigand SD, Therneau TM,
Knopman DS, et al. The bivariate distribution of amyloid-beta
and tau: relationship with established neurocognitive clinical syn-
dromes. Brain. 2019;142:3230–42. https://doi.org/10.1093/brain/
awz268.
5. Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G,
et al. Diagnostic performance of RO948 F 18 tau positron emission
tomography in the differentiation of Alzheimer disease from other
neurodegenerative disorders. JAMA Neurol. 2020. https://doi.org/
10.1001/jamaneurol.2020.0989.
6. Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M,
Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir
positron emission tomography for Alzheimer disease vs other neu-
rodegenerative disorders. JAMA. 2018;320:1151–62. https://doi.
org/10.1001/jama.2018.12917.
7. Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S,
Schaerf FW, et al. Relationships between flortaucipir PET tau bind-
ing and amyloid burden, clinical diagnosis, age and cognition.
Brain. 2017;140:748–63. https://doi.org/10.1093/brain/aww334.
8. Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT,
Fryer TD, et al. [(18)F]AV-1451 binding in vivo mirrors the ex-
pected distribution of TDP-43 pathology in the semantic variant of
primary progressive aphasia. J Neurol Neurosurg Psychiatry.
2018;89:1032–7. https://doi.org/10.1136/jnnp-2017-316402.
9. Schonhaut DR,McMillan CT, Spina S, Dickerson BC, Siderowf A,
Devous MD Sr, et al. (18) F-flortaucipir tau positron emission to-
mography distinguishes established progressive supranuclear palsy
from controls and Parkinson disease: a multicenter study. Ann
Neurol. 2017;82:622–34. https://doi.org/10.1002/ana.25060.
10. Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S,
Hanseeuw BJ, et al. Sex differences in the Association of Global
Amyloid and Regional Tau DepositionMeasured by positron emis-
sion tomography in clinically normal older adults. JAMA Neurol.
2019;76:542–51. https://doi.org/10.1001/jamaneurol.2018.4693.
11. Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, et al. Tau
PET in Alzheimer disease and mild cognitive impairment.
2256 Eur J Nucl Med Mol Imaging (2021) 48:2245–2258
Neurology. 2016;87:375–83. https://doi.org/10.1212/WNL.
0000000000002892.
12. Graff-Radford J, Arenaza-Urquijo EM, Knopman DS, Schwarz
CG, Brown RD, Rabinstein AA, et al . White matter
hyperintensities: relationship to amyloid and tau burden. Brain.
2019;142:2483–91. https://doi.org/10.1093/brain/awz162.
13. La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J,
et al. Prospective longitudinal atrophy in Alzheimer’s disease cor-
relates with the intensity and topography of baseline tau-PET. Sci
Transl Med. 2020;12. https://doi.org/10.1126/scitranslmed.
aau5732.
14. Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T,
Jogi J, et al. Greater tau load and reduced cortical thickness in
APOE epsilon4-negative Alzheimer’s disease: a cohort study.
Alzheimers Res Ther. 2018;10:77. https://doi.org/10.1186/
s13195-018-0403-x.
15. McSweeney M, Pichet Binette A, Meyer PF, Gonneaud J, Bedetti
C, Ozlen H, et al. Intermediate flortaucipir uptake is associated with
Abeta-PET and CSF tau in asymptomatic adults. Neurology.
2020;94:e1190–e200. ht tps : / /doi .org /10.1212/WNL.
0000000000008905.
16. Ossenkoppele R, Lyoo CH, Jester-Broms J, Sudre CH, Cho H, Ryu
YH, et al. Assessment of demographic, genetic, and imaging vari-
ables associated with brain resilience and cognitive resilience to
pathological tau in patients with Alzheimer disease. JAMA
Neurol. 2020;77:632–42. https://doi.org/10.1001/jamaneurol.
2019.5154.
17. Ossenkoppele R, Lyoo CH, Sudre CH, van Westen D, Cho H, Ryu
YH, et al. Distinct tau PET patterns in atrophy-defined subtypes of
Alzheimer’s disease. Alzheimers Dement. 2020;16:335–44. https://
doi.org/10.1016/j.jalz.2019.08.201.
18. Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta
N, Baker SL, et al. Tau PET patterns mirror clinical and neuroana-
tomical variability in Alzheimer’s disease. Brain. 2016;139:1551–
67. https://doi.org/10.1093/brain/aww027.
19. Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N,
Insel PS, et al. Associations between tau, Abeta, and cortical thick-
ness with cognition in Alzheimer disease. Neurology. 2019;92:
e601–e12. https://doi.org/10.1212/WNL.0000000000006875.
20. Scholl M, Ossenkoppele R, Strandberg O, Palmqvist S, Swedish
Bio F, Jogi J, et al. Distinct 18F-AV-1451 tau PET retention pat-
terns in early- and late-onset Alzheimer’s disease. Brain. 2017;140:
2286–94. https://doi.org/10.1093/brain/awx171.
21. Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S,
Chamoun M, Savard M, et al. Association of apolipoprotein E
epsilon4 with medial temporal tau independent of amyloid-beta.
JAMA Neurol. 2020;77:470–9. https://doi.org/10.1001/
jamaneurol.2019.4421.
22. Timmers T, Ossenkoppele R,Wolters EE, Verfaillie SCJ, Visser D,
Golla SSV, et al . Associat ions between quanti ta t ive
[(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s dis-
ease spectrum. Alzheimers Res Ther. 2019;11:60. https://doi.org/
10.1186/s13195-019-0510-3.
23. Whitwell JL, Graff-Radford J, Tosakulwong N, Weigand SD,
Machulda MM, Senjem ML, et al. Imaging correlations of tau,
amyloid, metabolism, and atrophy in typical and atypical
Alzheimer’s disease. Alzheimers Dement. 2018;14:1005–14.
https://doi.org/10.1016/j.jalz.2018.02.020.
24. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox
NC, et al. The diagnosis of mild cognitive impairment due to
Alzheimer’s disease: recommendations from the National Institute
on Aging-Alzheimer’s Association workgroups on diagnostic
guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:
270–9. https://doi.org/10.1016/j.jalz.2011.03.008.
25. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR
Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s
disease: recommendations from the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. https://
doi.org/10.1016/j.jalz.2011.03.005.
26. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B,
Haeberlein SB, et al. NIA-AA research framework: toward a bio-
logical definition of Alzheimer’s disease. Alzheimers Dement.
2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018.
27. Weiner MW, Veitch DP. Introduction to special issue: overview of
Alzheimer’s disease neuroimaging initiative. Alzheimers Dement.
2015;11:730–3. https://doi.org/10.1016/j.jalz.2015.05.007.
28. Sled JGZA, Evans AC. A nonparametric method for automatic
correction of intensity nonuniformity in MRI data. IEEE Trans
Med Imaging. 1998;17:10.
29. Segonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, et al.
A hybrid approach to the skull stripping problem in MRI.
Neuroimage. 2004;22:1060–75. https://doi.org/10.1016/j.
neuroimage.2004.03.032.
30. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C,
et al. Whole brain segmentation: automated labeling of neuroana-
tomical structures in the human brain. Neuron. 2002;33:341–55.
https://doi.org/10.1016/s0896-6273(02)00569-x.
31. Fischl B, Dale AM. Measuring the thickness of the human cerebral
cortex frommagnetic resonance images. Proc Natl Acad Sci U S A.
2000;97:11050–5. https://doi.org/10.1073/pnas.200033797.
32. Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ,
Knopman DS, et al. Defining imaging biomarker cut points for
brain aging and Alzheimer’s disease. Alzheimers Dement.
2017;13:205–16. https://doi.org/10.1016/j.jalz.2016.08.005.
33. Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R,
et al. Comparison of multiple tau-PET measures as biomarkers in
aging and Alzheimer’s disease. Neuroimage. 2017;157:448–63.
https://doi.org/10.1016/j.neuroimage.2017.05.058.
34. Sudre CH, Cardoso MJ, Bouvy WH, Biessels GJ, Barnes J,
Ourselin S. Bayesian model selection for pathological neuroimag-
ing data applied to white matter lesion segmentation. IEEE Trans
Med Imaging. 2015;34:2079–102. https://doi.org/10.1109/TMI.
2015.2419072.
35. Cleveland WS. Robust locally weighted regression and smoothing
scatterplots. J Am Stat Assoc. 1979;74:829–36. https://doi.org/10.
2307/2286407.
36. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA,
Arfanakis K, et al. Limbic-predominant age-related TDP-43 en-
cephalopathy (LATE): consensus working group report. Brain.
2019;142:1503–27. https://doi.org/10.1093/brain/awz099.
37. Karanth S, Nelson PT, Katsumata Y, Kryscio RJ, Schmitt FA,
Fardo DW, et al. Prevalence and clinical phenotype of quadruple
misfolded proteins in older adults. JAMANeurol. 2020. https://doi.
org/10.1001/jamaneurol.2020.1741.
38. Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical
reappraisal. J Neurochem. 2009;110:1129–34. https://doi.org/10.
1111/j.1471-4159.2009.06181.x.
39. Kirkwood TB. Understanding the odd science of aging. Cell.
2005;120:437–47. https://doi.org/10.1016/j.cell.2005.01.027.
40. Jellinger KA, Attems J. Prevalence of dementia disorders in the
oldest-old: an autopsy study. Acta Neuropathol. 2010;119:421–
33. https://doi.org/10.1007/s00401-010-0654-5.
41. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der
Flier WM, van Berckel BN, et al. Prevalence of amyloid PET pos-
itivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:
1939–49. https://doi.org/10.1001/jama.2015.4669.
42. Honer M, Gobbi L, Knust H, Kuwabara H, Muri D, Koerner M,
et al. Preclinical evaluation of (18)F-RO6958948, (11)C-
RO6931643, and (11)C-RO6924963 as novel PET radiotracers
for imaging tau aggregates in Alzheimer disease. J Nucl Med.
2018;59:675–81. https://doi.org/10.2967/jnumed.117.196741.
2257Eur J Nucl Med Mol Imaging (2021) 48:2245–2258
43. MarquieM, NormandinMD, Vanderburg CR, Costantino IM, Bien
EA, Rycyna LG, et al. Validating novel tau positron emission to-
mography tracer [F-18]-AV-1451 (T807) on postmortem brain tis-
sue. Ann Neurol. 2015;78:787–800. https://doi.org/10.1002/ana.
24517.
44. Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK,
Truocchio SP, et al. Positron emission tomography imaging with
[18F]flortaucipir and postmortem assessment of Alzheimer disease
neuropathologic changes. JAMA Neurol. 2020. https://doi.org/10.
1001/jamaneurol.2020.0528.
45. Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa
N, et al. Tau pathology and neurodegeneration contribute to cogni-
tive impairment in Alzheimer’s disease. Brain. 2017;140:3286–
300. https://doi.org/10.1093/brain/awx243.
46. Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe
S, et al. Tau PET in autosomal dominant Alzheimer’s disease: re-
lationship with cognition, dementia and other biomarkers. Brain.
2019;142:1063–76. https://doi.org/10.1093/brain/awz019.
47. Scott MR, Hampton OL, Buckley RF, Chhatwal JP, Hanseeuw BJ,
Jacobs HI, et al. Inferior temporal tau is associated with accelerated
prospective cortical thinning in clinically normal older adults.
Neuroimage. 2020;220:116991. https://doi.org/10.1016/j.
neuroimage.2020.116991.
48. Jack CR Jr, Wiste HJ, Therneau TM, Weigand SD, Knopman DS,
Mielke MM, et al. Associations of amyloid, tau, and
neurodegeneration biomarker profiles with rates of memory decline
among individuals without dementia. JAMA. 2019;321:2316–25.
https://doi.org/10.1001/jama.2019.7437.
49. Ramanan VK, Castillo AM, Knopman DS, Graff-Radford J, Lowe
VJ, Petersen RC, et al. Association of apolipoprotein E varepsilon4,
educational level, and sex with tau deposition and tau-mediated
metabolic dysfunction in older adults. JAMA Netw Open. 2019;2:
e1913909. https://doi.org/10.1001/jamanetworkopen.2019.13909.
50. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the
clinical diagnosis of Alzheimer disease at National Institute on
Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp
Neurol. 2012;71:266–73. https://doi.org/10.1097/NEN.
0b013e31824b211b.
51. Busche MA, Hyman BT. Synergy between amyloid-beta and tau in
Alzheimer’s disease. Nat Neurosci. 2020. https://doi.org/10.1038/
s41593-020-0687-6.
52. Smith R, Scholl M, Leuzy A, Jogi J, Ohlsson T, Strandberg O, et al.
Head-to-head comparison of tau positron emission tomography
tracers [(18)F]flortaucipir and [(18)F]RO948. Eur J Nucl Med
Mol Imaging. 2020;47:342–54. https://doi.org/10.1007/s00259-
019-04496-0.
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Affiliations
Rik Ossenkoppele1,2 & Antoine Leuzy1 & Hanna Cho3 & Carole H. Sudre4,5,6 & Olof Strandberg1 & Ruben Smith1 &
Sebastian Palmqvist1 & Niklas Mattsson-Carlgren1,7,8 & Tomas Olsson9 & Jonas Jögi10 & Erik Stormrud1,11 &
Young Hoon Ryu12 & Jae Yong Choi12,13 & Adam L. Boxer14 &Maria L. Gorno-Tempini14 & Bruce L. Miller14 &
David Soleimani-Meigooni14 & Leonardo Iaccarino14 & Renaud La Joie14 & Edilio Borroni15 & Gregory Klein15 &
Michael J. Pontecorvo16 & Michael D. Devous Sr16 & Sylvia Villeneuve17 & Chul Hyoung Lyoo3 & Gil D. Rabinovici15,18,19 &
Oskar Hansson1,11 & for the Alzheimer’s Disease Neuroimaging Initiative & for the PREVENT-AD research group
1 Clinical Memory Research Unit, Lund University, Lund, Sweden
2 Alzheimer Center Amsterdam, Department of Neurology,
Amsterdam Neuroscience, Amsterdam UMC, VU University
Medical Center, Vrije Universiteit Amsterdam,
Amsterdam, The Netherlands
3 Department of Neurology, Gangnam Severance Hospital, Yonsei
University College of Medicine, Seoul, South Korea
4 School of Biomedical Engineering and Imaging Sciences, King’s
College London, London, UK
5 Dementia Research Centre, Department of Neurodegenerative
Disease, UCL Institute of Neurology, London, UK
6 Centre for Medical Image Computing, Department of Medical
Physics, University College London, London, UK
7 Department of Neurology, Skåne University Hospital,
Lund, Sweden
8 Wallenberg Centre for Molecular Medicine, Lund University,
Lund, Sweden
9 Department of Radiation Physics, Skåne University Hospital,
Lund, Sweden
10 Department of Clinical Physiology and Nuclear Medicine, Skåne
University Hospital, Lund, Sweden
11 Memory Clinic, Skåne University Hospital, Malmö, Sweden
12 Department of Nuclear Medicine, Gangnam Severance Hospital,
Yonsei University College of Medicine, Seoul, South Korea
13 Division of applied RI, Korea Institute Radiological and Medical
Sciences, Seoul, South Korea
14 Department of Neurology, Memory and Aging Center, University
of California San Francisco, San Francisco, USA
15 F. Hoffmann-La Roche Ltd, Basel, Switzerland
16 Avid Radiopharmaceuticals, Philadelphia, PA, USA
17 Departments of Psychiatry and Neurology & Neurosurgery,
Douglas Mental Health University Institute, McGill University,
Montreal, Quebec, Canada
18 Department of Radiology and Biomedical Imaging, University of
California San Francisco, San Francisco, USA
19 Molecular Biophysics and Integrated Bioimaging Division,
Lawrence Berkeley National Laboratory, Berkeley, CA, USA
2258 Eur J Nucl Med Mol Imaging (2021) 48:2245–2258
